Table 2.
Outcome | Groups | Differences Within Groups | Difference Between Groups | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Week 0 | Week 1 | Week 4 | Week 1 minus Week 0 | Week 4 minus Week 0 | MFR minus Sham | ||||||||
MFR | Sham | MFR | Sham | MFR | Sham | MFR | Sham | MFR | Sham | Week 0 | Week 1 | Week 4 | |
RDQ (0–5) | 2.3 (1.0) |
1.8 (1.0) |
0.6 (0.6) |
1.6 (0.8) |
0.6 (0.5) |
1.7 (1.0) |
−1.7 (0.7) |
−0.2 (0.7) |
−1.6 (0.8) |
−0.1 (0.6) |
0.5 (−0.2 to 1.2) |
−1.0** (−1.5 to −0.5) |
−1.1** (−1.7 to −0.5) |
GIQLI (0–144) | 102.3 (19.0) |
94.3 (20.9) |
112.7 (13.2) |
103.3 (22.7) |
116.3 (14.6) |
98.1 (20.7) |
10.3 (8.2) |
9 (18.1) |
13.9 (12.8) |
3.8 (8.7) |
8.0 (−7.0 to 23.0) |
9.3 (−4.5 to 23.2) |
18.1* (4.8 to 31.5) |
PPI (mg/week) | 88 (78) |
135 (120) |
36 (52) |
132 (122) |
33 (51) |
131 (112) |
−52 (49) |
−3 (10) |
−55 (55) |
−4 (43) |
−47 (−122 to 29) |
−96* (−166 to −26) |
−97* (−162 to −32) |
MFR = myofascial release group, Sham = sham group, RDQ = Reflux Disease questionnaire; GIQLI = Gastrointestinal Quality of Life Index, PPI = Proton Pump Inhibitors.
P-values were obtained from two-way ANOVA tests: **p ≤ 0.001, *p ≤ 0.01.